Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India

Kuntegowdanahalli, Lakshmaiah Chinnagiriyappa; Kanakasetty, Govind Babu; Thanky, Aditi Harsh; Dasappa, Lokanatha; Jacob, Linu Abraham; Mallekavu, Suresh Babu; Lakkavalli, Rajeev Krishnappa; Kadabur, Lokesh N; Haleshappa, Rudresha Antapura

doi:10.3332/ecancer.2016.679

Cited by 28 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean age of our patients was 39.76 years. This is similar to other studies conducted in Southeast Asia but lower than compared to Western countries such as Sweden where mean age of presentation is reported to be 60 years [7][8][9]. The difference could be attributed to demographic characteristics of developing countries or genetic factors.…”

Section: Discussionsupporting

confidence: 88%

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Saleem

Hafeez

Raza

et al. 2020

Cureus

View full text Add to dashboard Cite

Introduction: The hallmark of chronic myeloid leukemia (CML) is the development of the fusion gene, BCR-ABL which has unopposed tyrosine kinase activity. The first tyrosine kinase inhibitor (TKI) imatinib is claimed to have superior efficacy and side effect profile as compared to traditional treatment options. This study was conducted to see our patients' molecular response to imatinib treatment. The objective of this study was to determine the frequency of complete molecular response in patients after six months of imatinib therapy. Methods: A descriptive case series was designed and conducted in Oncology department, Jinnah hospital Lahore (May-November 2016). Newly diagnosed patients of CML aged between 20 and 65 years were enrolled. They were prescribed 400 mg imatinib daily and complete molecular response was assessed after six months of treatment. Results: Mean age was 39.76 ± 9.072 years. Some 66 of them were males while 69 were females. Some 40 patients (29.6%) were found to be in complete molecular response after six months of imatinib therapy. Conclusion: Imatinib at a dose of 400 mg/day is optimal as the primary therapy for CML.

show abstract

Section: Discussionsupporting

confidence: 88%

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Saleem

Hafeez

Raza

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Our findings are in line with previous studies from European population and Western population. [ 5 7 14 16 ] According to the EUTOS score, 210 patients (80.7%) and 50 patients (19.2%) were in low-risk and high-risk score respectively, which is similar to the study from European population but in contrast to study from Chinese population by Tao et al . [ 10 11 12 13 ]…”

Section: Discussionsupporting

confidence: 71%

“…These studies indicated the significance of Sokal and Euro score in forecasting the outcome in CML patients and also questioned the validity of the EUTOS scoring system. [ 14 15 16 ] However, contradictory results were suggested by Hoffman et al . in German population.…”

Section: Discussionmentioning

confidence: 99%

“…Worldwide, several studies from different regions have compared the clinical significance of these prognostic scoring systems and found mixed opinions regarding their utility. [ 9 10 11 12 13 14 15 16 ] Few studies observed that EUTOS score is better than Sokal and Euro score in predicting the prognosis of CML patients; however, Sokal and Euro scores were found better than EUTOS in other studies. [ 7 9 10 11 12 13 14 15 ] Sokal and Euro score were successfully used to differentiate all risk patients treated with imatinib according to 5-year overall survival (OS); however, EUTOS score has failed to show a significant association.…”

Section: Introductionmentioning

confidence: 99%

“…To the best of our knowledge, there are very limited data from Asian population regarding the comparative analysis of prognostic scores in CML patients receiving front-line imatinib therapy. [ 14 15 16 ] In view of this, we assessed the most widely used prognostic risk models (Sokal score, Euro, and EUTOS score) and compared their efficacy as a predictive and prognostic tool in a cohort of 260 Indian CML-CP patients on imatinib.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib

Chhikara

Sazawal

Singh

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

Introduction:The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy.Aim:To perform a comparative assessment of the Sokal, Euro and EUTOS prognostic score in Indian CML-CP patients on imatinib.Methods:This is a retrospective study performed in 260 Ph+ CML-CP patients who were administered oral imatinib (400 mg/day).Results:166/260 were males and 94/260 were females (M: F::1.6:1) with median age 35 years (range 20-70). 92 (35.38%), 125 (48.07%) and 43 (16.5%) patients were divided into low, intermediate and high risk Sokal score respectively. 102 (39.23%), 106 (40.76%) and 52 (20%) patients were discriminated into low, intermediate and high risk Euro score respectively. 210 (80.7%) and 50 (19.2%) patients were divided into low and high risk EUTOS score. Cumulative incidence of MMR for low, intermediate and high-risk Sokal score was 87%, 76% and 84% respectively (P = 0.016). Incidence of MMR in low, intermediate and high-risk Euro score was 93%, 85% and 68% respectively (P = 0.001). Incidence of MMR was 80 % and 81% for low and high risk EUTOS score (P = 0.764). Both EFS and OS are significantly correlated with Sokal score (P = 0.004, P = 0.007) and Euro score (P = 0.009, P = 0.001) but not with EUTOS score (P = 0.581, P = 0.927).Conclusion:The present study highlights the significant prognostic role of Sokal and Euro score in predicting the treatment outcome of the CML- CP patients on imatinib.

show abstract

Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India

2020

View full text Add to dashboard Cite

Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India

Cited by 28 publications

References 33 publications

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib

Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India

Contact Info

Product

Resources

About